Innovative Liquid Biopsy Test - RGCC Cambiseq

Order a test

RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.

The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy.

RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.

Sample of the report Order a test

Test Details

Sample Type

Blood, tissue, FFPE Tissue (Formalin-Fixed Paraffin-Embedded)

Analysis period

Approx. 2–3 weeks

Cancer type

All types of Cancers

Final results

2–4 weeks

Sample Size

Blood: 7–10 ml peripheral whole blood, Fresh tissue: Minimum 400mg, FFPE: Minimum 100mg (or 1 block)

Price*

3100€

* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.

Find out more about the science behind RGCC tests

Can brain tumours also be tested with a blood sample?

No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.

Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?

Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.

Which test is the most comprehensive test?

The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.

How do online consultations work?

Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs.

Will online consultations take place via Zoom, Skype, or another method?

Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.

Didn't find an answer to your question? Contact us directly.

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more